samedan logo
 
 
spacer
home > pmps > winter 2021 > anti-counterfeiting and the use of optimised laser-marking settings and materials for medical devices
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Anti-Counterfeiting and the Use of Optimised Laser-Marking Settings and Materials for Medical Devices

Anti-counterfeiting is one of the main public health targets for medical devices that can be achieved through the implementation of the unique device identification (UDI) system provided in respect to the EUís new Medical Device Regulation (MDR) and USí Code of Federal Regulations Title 21 referring to labelling for medical devices (21 CFR 801 Subpart B). Other targets like safety communication promotion, reduction of inappropriate use of the device, management of adverse events, incident reporting, and efficient device recalls can be achieved through the use of a unique identifier combined with the creation of a central UDI database.

The UDI must be placed on the medical device and on its related packaging and should include both a human readable interpretation (HRI) text for HRI of the data characters and automatic identification and data capture (AIDC) text for the automatic identification through bar codes, smart cards, biometrics, and radio frequency identification (RFID), also known as AIDC technologies.

A device can be more easily counterfeited if the UDI information is stamped or marked on a label applied to the device, just by removing/substituting the label. On the other hand, it is much more difficult to falsify products if the same information is directly laser marked on the surface of the medical device itself. There are medical devices that must be directly marked with a unique device identifier (CFR 21 Sec. 801.45 or EU MDR Part C 4.10 about the UDI system in reusable devices); in general if the device is intended to be used more than once and intended to be cleaned or disinfected before each use.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Luca Chiochia graduated from the Politecnico di Milano University, Italy, in Management Engineering and covers the position of Business Development Manager at ELIX Polymers for the healthcare/medical business since 2017. He is fluent in six languages and has over 15 years of experience in industrial applications from multiple sectors' perspectives including thermoplastics, thermoset plastics, composites, electrical insulation, and electronics assembly.
spacer
Luca Chiochia
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Orbit Discovery Awarded Innovate UK Grant to Expand High Throughput Cell-Based Functional Screening Platform Capabilities in Peptide Drug Discovery

Oxford, United Kingdom, 13th June, 2022: Orbit Discovery Ltd., (ďOrbitĒ) a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, has been awarded a Smart grant by Innovate UK, the UKís innovation agency. Totalling £472,000, the grant will facilitate the implementation of droplet-based microfluidics for cell-based functional screening and significantly expand the capabilities and throughput of Orbitís peptide display platform. The project aims to advance the discovery of peptide therapeutic candidates including the most challenging of drug targets by improving overall process efficiency whilst reducing the risk and associated costs.
More info >>

White Papers

Technology Solutions - Driving efficiencies, quality and operational excellence

Worldwide Clinical Trials Ltd

Clinical trials involve the entry, analysis and reporting of millions of pieces of data; year-on-year, the amount of data required to manage efficacy and safety increases exponentially. Recently, solutions available to support this activity have grown in numbers and complexity. The rise of Tablets and Smart Phones combined with the growth of Cloud or SAS solutions has resulted in the technology landscape required to support complex, global studies becoming more confusing.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement